XXXX with @entity1543 percutaneous injection.

@entity1 @entity39 @entity5 @entity843 @entity4461 @entity157 @entity1543
Percutaneous ablation using @entity1543 is an attractive method because of its low morbidity and low number of sessions required to induce @entity39 . Moreover, the real-time fluoroscopy CT scan could improve the technique by improving distribution of the necrotizing agent within the @entity5 . AIM: To determine the feasibility and the long-term results of the @entity1543 percutaneous injection under CT fluoroscopy guidance in a series of cirrhotic @entity1 with @entity157 in a single French center. METHODS: One hundred and two @entity1 with @entity157 were evaluated for treatment between 1999 and 2000. The selection criteria for fluoroscopy CT scan-directed percutaneous @entity1543 ablation were: 1) one to three nodules<5 centimeters; 2) @entity1 -Pugh class<13; 3) prothrombin index > 40% and platelet count > 50000 per mm(3) and 4) contraindication to both resection and liver transplantation. Post treatment follow-up included ultrasonography, magnetic resonance and alphafetoprotein levels every 3 months. Recurrence and survival rates were estimated using the Kaplan-Meier method. RESULTS: Forty-nine @entity1 (48%) could benefit from a curative treatment, most of them (37/49) being eligible for fluoroscopy CT scan-directed percutaneous @entity1543 . The mean follow up was 24.4 +/- 2.7 months. @entity39 was achieved in 28 @entity1 (76%) after a mean of 1.6 sessions. In these 28 @entity1 , the recurrence rates were 34% and 48% and survival rates were 76% and 70%, at 24 and 36 months, respectively. No serious complications occurred during or after the treatment. CONCLUSIONS: Percutaneous ablation using @entity1543 using CT fluoroscopy guidance may be considered as a short term efficient, low risk treatment and can be applied even in @entity1 with @entity843 or severe @entity4461 . However, the high rate of recurrence and the early occurrence of multifocal @entity157 underline the limits of this method as well as of all other percutaneous strategies.
